biostudies-literatureButtimer CIrish Research CouncilJanssen BiotechScience Foundation IrelandNIDDK NIH HHSNIH HHS936083https://www.ebi.ac.uk/biostudies/studies/S-EPMC9355613biostudies-literatureUnknown13Escherichia coli and <i>Enterococcus faecalis</i> have been implicated as important players in human gut health that have been associated with the onset of inflammatory bowel disease (IBD). Bacteriophage (phage) therapy has been used for decades to target pathogens as an alternative to antibiotics, but the ability of phage to shape complex bacterial consortia in the lower gastrointestinal tract is not clearly understood. We administered a cocktail of six phages (either viable or heat-inactivated) targeting pro-inflammatory <i>Escherichia coli</i> LF82 and <i>Enterococcus faecalis</i> OG1RF as members of a defined community in both a continuous fermenter and a murine colitis model. The two target strains were members of a six species simplified human microbiome consortium (SIHUMI-6). In a 7Frontiers in microbiologyImpact of a phage cocktail targeting <i>Escherichia coli</i> and <i>Enterococcus faecalis</i> as members of a gut bacterial consortium <i>in vitro</i> and <i>in vivo</i>.PMC9355613SFI/12/RC/2273SFI/14/SPAPC/B3032P30 DK034987SFI/15/ERCD/3189GOIPD/2019/1097P01 DK094779P40 OD010995Herzog JWButtimer CSmith LOka ARoss RPHill CMurray EBettio PHBolocan ASShkoporov ASutton TSartor RBColom JDraper LALiu BfalseImpact of a phage cocktail targeting <i>Escherichia coli</i> and <i>Enterococcus faecalis</i> as members of a gut bacterial consortium <i>in vitro</i> and <i>in vivo</i>.Escherichia coli and <i>Enterococcus faecalis</i> have been implicated as important players in human gut health that have been associated with the onset of inflammatory bowel disease (IBD). Bacteriophage (phage) therapy has been used for decades to target pathogens as an alternative to antibiotics, but the ability of phage to shape complex bacterial consortia in the lower gastrointestinal tract is not clearly understood. We administered a cocktail of six phages (either viable or heat-inactivated) targeting pro-inflammatory <i>Escherichia coli</i> LF82 and <i>Enterococcus faecalis</i> OG1RF as members of a defined community in both a continuous fermenter and a murine colitis model. The two target strains were members of a six species simplified human microbiome consortium (SIHUMI-6). In a 72022-01-01T00:00:00Z20222026-05-09T14:10:56.88Z2024-11-19T22:28:39.364ZS-EPMC93556133593521710.3389/fmicb.2022.936083